NCT-505 is an Orally Bioavailable aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitor with Potent Cellular Activity (IC50 = 7 nM). NCT-505 demonstrated target engagement in a cellular thermal shift assay (CETSA), inhibited the formation of 3D spheroid cultures of OV-90 cancer cells, and potentiated the cytotoxicity of paclitaxel in SKOV-3-TR, a paclitaxel resistant ovarian cancer cell line. NCT-505 also exhibit high specificity over other ALDH isozymes and unrelated dehydrogenases.
